Recent developments in leishmaniasis

Current Opinion in Infectious Diseases

Volumn 15, Issue 5, 2002, Pages 485-490

  Melby, Peter C ^a  

^a University of Texas Health Science Center at San Antonio   (United States)

Author keywords

Immunity; Leishmania; Leishmaniasis; Sand fly; Treatment; Vaccines

Indexed keywords

A2 PROTEIN; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANTILEISHMANIAL AGENT; ANTIMONY; CD4 ANTIGEN; CD8 ANTIGEN; FLUCONAZOLE; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 4; LEISHMANIA VACCINE; LIPOPOLYSACCHARIDE; LMSTI 1 PROTEIN; MAXADILAN; MEGLUMINE ANTIMONATE; METHYLBENZETHONIUM CHLORIDE; MILTEFOSINE; P36 LACK VACCINE; PAROMOMYCIN; PLASMID DNA; PROTOZOAL PROTEIN; STIBOGLUCONATE SODIUM; TSA PROTEIN; UNCLASSIFIED DRUG; PROTOZOAL VACCINE;

BUNYAVIRUS; CLINICAL FEATURE; CLINICAL TRIAL; CLONAL VARIATION; COMORBIDITY; DENDRITIC CELL; DISEASE CARRIER; DRUG CHOICE; DRUG COST; EPIDEMIOLOGICAL DATA; GENE IDENTIFICATION; GENETIC HETEROGENEITY; HEALTH CARE COST; HOST RESISTANCE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNOPATHOGENESIS; INFECTION CONTROL; LEISHMANIA; LEISHMANIASIS; NONHUMAN; PARASITE SERODIAGNOSIS; PARASITE VIRULENCE; PATHOGENESIS; REVIEW; VACCINIA VIRUS; VIRUS RECOMBINANT; VISCERAL LEISHMANIASIS; ANIMAL; GENETICS; IMMUNOLOGY; PATHOGENICITY; PHYSIOLOGY;

ANIMALS; HUMANS; LEISHMANIA; LEISHMANIASIS; PROTOZOAN VACCINES;

EID: 0036792366     PISSN: 09517375     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001432-200210000-00005     Document Type: Review

References (62)

1. Schonian G, Schnur L, el Fari M, et al. Genetic heterogeneity in the species Leishmania tropica revealed by different PCR-based methods. Trans R Soc Trop Med Hyg 2001; 95:217-224.
2. Kebaier C, Louzir H, Chenik M, et al. Heterogeneity of wild Leishmania major isolates in experimental murine pathogenicity and specific immune response. Infect Immun 2001; 69:4906-4915.
3. Garin YJ, Sulahian A, Pratlong F, et al. Virulence of Leishmania infantum is expressed as a clonal and dominant phenotype in experimental infections. Infect Immun 2001; 69:7365-7373.
4. Sacks D, Kamhawi S. Molecular aspects of parasite-vector and vector-host interactions in leishmaniasis. Annu Rev Microbiol 2001; 55:453-483.
5. Turco SJ, Spath GF, Beverley SM. Is lipophosphoglycan a virulence factor? A surprising diversity between Leishmania species. Trends Parasitol 2001; 17:223-226.
6. Garami A, IIg T. The role of phosphomannose isomerase in Leishmania mexicana glycoconjugate synthesis and virulence. J Biol Chem 2001; 276:6566-6575.
7. Barr SD, Gedamu L. Cloning and characterization of three differentially expressed peroxidoxin genes from Leishmania chagasi. Evidence for an enzymatic detoxification of hydroxyl radicals. J Biol Chem 2001; 276:34279-34287.
8. Boucher N, Wu Y, Dumas C, et al. A common mechanism of stage-regulated gene expression in Leishmania mediated by a conserved 3' UTR element. J Biol Chem 2002; 277:19511-19520.
9. Myung KS, Beetham JK, Wilson ME, Donelson JE. Comparison of the post-transcriptional regulation of the mRNAs for the surface proteins PSA (GP46) and MSP (GP63) of Leishmania chagasi. J Biol Chem 2002; 277:16489-16497.
10. Brooks DR, Denise H, Westrop GD, et al. The stage-regulated expression of Leishmania mexicana CPB cysteine proteases is mediated by an intercistronic sequence element. J Biol Chem 2001; 276:47061-47069.
11. Rodriguez NM, Docampo R, Lu Hg HG, Scott DA. Overexpression of the Leishmania amazonensis Ca2+-ATPase gene Imaa1 enhances virulence. Cell Microbiol 2002; 4:117-126.
12. Joshi PB, Kelly BL, Kamhawi S, et al. Targeted gene deletion in Leishmania major identifies leishmanolysin (GP63) as a virulence factor. Mol Biochem Parasitol 2002; 120:33-40.
13. Travi BL, Tabares CJ, Cadena H, et al. Canine visceral leishmaniasis in Colombia: relationship between clinical and parasitologic status and infectivity for sand flies. Am J Trop Med Hyg 2001; 64:119-124.
14. Palatnik-de-Sousa CB, dos Santos WR, Franca-Silva JC, et al. Impact of canine control on the epidemiology of canine and human visceral leishmaniasis in Brazil. Am J Trop Med Hyg 2001; 65:510-517.
15. Maroli M, Mizzon V, Siragusa C, et al. Evidence for an impact on the incidence of canine leishmaniasis by the mass use of deltamethrin-impregnated dog collars in southern Italy. Med Vet Entomol 2001; 15:358-363.
16. Gaskin AA, Schantz P, Jackson J, et al. Visceral leishmaniasis in a New York foxhound kennel. J Vet Intern Med 2002; 16:34-44.
17. Romero GA, Vinitius De Farias Guerra M, Gomes Paes M, de Oliveira Macedo V. Comparison of cutaneous leishmaniasis due to Leishmania (Viannia) braziliensis and L. (V) guyanensis in Brazil: clinical findings and diagnostic approach. Clin Infect Dis 2001; 32:1304-1312.
18. Weigle KA, Labrada LA, Lozano C, et al. PCR-based diagnosis of acute and chronic cutaneous leishmaniasis caused by Leishmania (Viannia). J Clin Microbiol 2002; 40:601-606.
19. Anstead GM, Chandrasekar B, Zhao W, et al. Malnutrition alters the innate immune response and increases early visceralization following Leishmania donovani infection. Infect Immun 2001; 69:4709-4718.
20. de La Rosa R, Pineda JA, Delgado J, et al. Incidence of and risk factors for symptomatic visceral leishmaniasis among human immunodeficiency virus type 1-infected patients from Spain in the era of highly active antiretroviral therapy. J Clin Microbiol 2002; 40:762-767.
21. de la Rosa R, Pineda JA, Delgado J, et al. Influence of highly active antiretroviral therapy on the outcome of subclinical visceral leishmaniasis in human immunodeficiency virus-infected patients. Clin Infect Dis 2001; 32:633-635.
22. Pineda JA, Macias J, Morillas F, et al. Evidence of increased risk for Leishmania infantum infection among HIV-seronegative intravenous drug users from southern Spain. Eur J Clin Microbiol Infect Dis 2001 20:354-357.
23. Cruz I, Morales MA, Noguer I, et al. Leishmania in discarded syringes from intravenous drug users. Lancet 2002; 59:1124-1125.
24. Zijlstra EE, el-Hassan AM. Leishmaniasis in Sudan. Post kala-azar dermal leishmaniasis. Trans R Soc Trop Med Hyg 2001; 95 (Suppl. 1):S59-S76.
25. Kumar R, Pai K, Pathak K, Sundar S. Enzyme-linked immunosorbent assay for recombinant K39 antigen in diagnosis and prognosis of Indian visceral leishmaniasis. Clin Diagn Lab Immunol 2001; 8:1220-1224.
26. Salotra P, Sreenivas G, Nasim AA, et al. Evaluation of enzyme-linked immunosorbent assay for diagnosis of post-kala azar dermal leishmaniasis with crude or recombinant k39 antigen. Clin Diagn Lab Immunol 2002; 9:370-373.
27. Salotra P, Sreenivas G, Pogue GP, et al. Development of a species-specific PCR assay for detection of Leishmania donovani in clinical samples from patients with kala-azar and post-kala-azar dermal leishmaniasis. J Clin Microbiol 2001; 39:849-854.
28. Alrajhi AA, Ibrahim EA, De Vol EB, et al. Fluconazole for the treatment of cutaneous leishmaniasis caused by Leishmania major. N Engl J Med 2002; 346:891-895.
29. Romero GA, Guerra MV, Paes MG, Macedo VO. Comparison of cutaneous leishmaniasis due to Leishmania (Viannia) braziliensis and L. (V) guyanensis in Brazil: therapeutic response to meglumine antimoniate. Am J Trop Med Hyg 2001; 65:456-465.
30. Palacios R, Osorio LE, Grajalew LF, Ochoa MT. Treatment failure in children in a randomized clinical trial with 10 and 20 days of meglumine antimonate for cutaneous leishmaniasis due to Leishmania viannia species. Am J Trop Med Hyg 2001; 64:187-193.
31. Soto J, Toledo J, Gutierrez P, et al. Treatment of American cutaneous leishmaniasis with miltefosine, an oral agent. Clin Infect Dis 2001; 33:E57-E61.
32. Arana BA, Mendoza CE, Rizzo NR, Kroeger A. Randomized, controlled, double-blind trial of topical treatment of cutaneous leishmaniasis with paromomycin plus methylbenzethonium chloride ointment in Guatemala. Am J Trop Med Hyg 2001; 65:466-470.
33. Sundar S. Drug resistance in indian visceral leishmaniasis. Trop Med Int Health 2001; 6:849-854.
34. Sundar S, Agrawal G, Rai M, et al. Treatment of Indian visceral leishmaniasis with single or daily infusions of low dose liposomal amphotericin B: randomised trial. BMJ 2001; 323:419-422.
35. Uzonna JE, Wei G, Yurkowski D, Bretscher P. Immune elimination of Leishmania major in mice: implications for immune memory, vaccination, and reactivation disease. J Immunol 2001; 167:6967-6974.
36. Belkaid Y, Von Stebut E, Mendez S, et al. CDS(+) T cells are required for primary immunity in C57BL/6 mice following low-dose, intradermal challenge with Leishmania major. J Immunol 2002; 168:3992-4000.
37. Uzonna JE, Bretscher PA. Anti-IL-4 antibody therapy causes regression of chronic lesions caused by medium-dose Leishmania major infection in BALB/c mice. Eur J Immunol 2001; 31:3175-3184.
38. Biedermann T, Zimmermann S, Himmelrich H, et al. IL-4 instructs TH1 responses and resistance to Leishmania major in susceptible BALB/c mice. Nat Immunol 2001; 2:1054-1060.
39. Nishikomori R, Gurunathan S, Nishikomori K, Strober W. BALB/c mice bearing a transgenic IL-12 receptor beta 2 gene exhibit a nonhealing phenotype to Leishmania major infection despite intact IL-12 signaling. J Immunol 2001; 166:6776-6783.
40. Jebbari H, Stagg AJ, Davidson RN, Knight SC. Leishmania major promastigotes inhibit dendritic cell motility in vitro. Infect Immun 2002; 70:1023-1026.
41. Ponte-Sucre A, Heise D, Moll H, Leishmania major lipophosphoglycan modulates the phenotype and inhibits migration of murine Langerhans cells, Immunology 2001; 104:462-467.
42. Moll H, Scharner A, Kampgen E, Increased interleukin 4 (IL-4) receptor expression and IL-4-induced decrease in IL-12 production by Langerhans cells infected with Leishmania major. Infect Immun 2002; 70:1627-1630.
43. Belkaid Y, Hoffmann KF, Mendez S, et al. The role of interleukin (IL)-10 in the persistence of Leishmania major in the skin after healing and the therapeutic potential of anti-IL-10 receptor antibody for sterile cure. J Exp Med 2001; 194:1497-1506.
44. Murphy ML, Wille U, Villegas EN, et al. IL-10 mediates susceptibility to Leishmania donovani infection. Eur J Immunol 2001; 31:2848-2856.
45. Jones DE, Ackermann MR, Wille U, et al. Early enhanced Th1 response after Leishmania amazonensis infection of C57BL/6 interleukin-10-deficient mice does not lead to resolution of infection. Infect Immun 2002; 70:2151-2158.
46. Bourreau E, Prevot G, Gardon J, et al. High intralesional interleukin-10 messenger RNA expression in localized cutaneous leishmaniasis is associated with unresponsiveness to treatment. J Infect Dis 2001; 184:1628-1630.
47. Iniesta V, Carlos Gomez-Nieto L, Molano I, et al. Arginase I induction in macrophages, triggered by Th2-type cytokines, supports the growth of intracellular Leishmania parasites. Parasite Immunol 2002; 24:113-118.
48. Iniesta V, Gomez-Nieto LC, Corraliza I. The inhibition of arginase by N(omega)-hydroxy-I-arginine controls the growth of Leishmania inside macrophages. J Exp Med 2001; 193:777-784.
49. Buates S, Matlashewski G. General suppression of macrophage gene expression during Leishmania donovani infection. J Immunol 2001; 166:3416-3422.
50. Balestieri FM, Queiroz AR, Scavone C, et al. Leishmania (L.) amazonensis-induced inhibition of nitric oxide synthesis in host macrophages. Microbes Infect 2002; 4:23-29.
51. Gantt KR, Goldman TL, McCormick ML, et al. Oxidative responses of human and murine macrophages during phagocytosis of Leishmania chagasi. J Immunol 2001; 167:893-901.
52. Handman E. Leishmaniasis: current status of vaccine development. Clin Microbiol Rev 2001; 14:229-243.
53. Gonzalo RM, del Real G, Rodriguez JR, et al. A heterologous prime-boost regime using DNA and recombinant vaccinia virus expressing the Leishmania infantum P36/LACK antigen protects BALB/c mice from cutaneous leishmaniasis. Vaccine 2002; 20:1226-1231.
54. Melby PC, Yang J, Zhao W, et al. Leishmania donovani p36(LACK) DNA vaccine is highly immunogenic but not protective against experimental visceral leishmaniasis. Infect Immun 2001; 69:4719-4725.
55. Mendez S, Gurunathan S, Kamhawi S, et al. The potency and durability of DNA- and protein-based vaccines against Leishmania major evaluated using low-dose, intradermal challenge. J Immunol 2001; 166:5122-5128.
56. Campos-Neto A, Porrozzi R, Greeson K, et al. Protection against cutaneous leishmaniasis induced by recombinant antigens in murine and nonhuman primate models of the human disease. Infect Immun 2001; 69:4103-4108.
57. Rafati S, Salmanian A, Taheri T, et al. A protective cocktail vaccine against murine cutaneous leishmaniasis with DNA encoding cysteine proteinases of Leishmania major. Vaccine 2001; 19:3369-3375.
58. Ghosh A, Zhang WW, Matlashewski G. Immunization with A2 protein results in a mixed Th1/Th2 and a humoral response which protects mice against Leishmania donovani infections. Vaccine 2001; 20:59-66.
59. Ghosh A, Labrecque S, Matlashewski G. Protection against Leishmania donovani infection by DNA vaccination: increased DNA vaccination efficiency through inhibiting the cellular p53 response. Vaccine 2001; 19:3169-3178.
60. Paraguai de Souza E, Bernardo RR, Palatnik M, Palatnik de Sousa CB. Vaccination of Balb/c mice against experimental visceral leishmaniasis with the GP36 glycoprotein antigen of Leishmania donovani. Vaccine 2001; 19:3104-3115.
61. Valenzuela JG, Belkaid Y, Garfield MK, et al. Toward a defined anti-Leishmania vaccine targeting vector antigens: characterization of a protective salivary protein. J Exp Med 2001; 194:331-342.
62. Morris RV, Shoemaker CB, David JR, et al. Sandfly maxadilan exacerbates infection with Leishmania major and vaccinating against it protects against L. major infection. J Immunol 2001; 167:5226-5230.